全球范围内的多重耐药恶性疟原虫疟疾流行率不断上升,是全球控制疟疾的严重威胁,尤其是在像巴基斯坦这样的贫穷国家。在许多国家，耐药是一个巨大的问题，占疟疾病例的90%以上。在巴基斯坦,对霍洛金的耐药性正在上升，据报道高达16-62%的恶性疟原虫。据报道,4-25%的恶性疟原虫也对磺胺多辛-乙胺嘧啶耐药,并在接受奎宁治疗的恶性疟原虫疟疾患者中观察到几例寄生虫清除延迟.在本文中，我们介绍了基于青蒿素的联合治疗（ACT）的概念，并强调对所有恶性疟原虫疟疾患者使用经验性联合治疗，以防止耐药性的发展并获得附加和协同杀死寄生虫。
The increasing prevalence of multi-resistant Plasmodium falciparum malaria worldwide is a serious public health threat to the global control of malaria, especially in poor countries like Pakistan. In many countries choloroquine-resistance is a huge problem, accounting for more than 90% of malaria cases. In Pakistan, resistance to choloroquin is on the rise and reported in up to 16- 62% of Plasmodium falciparum. four to 25% of Plasmodium falciparum also reported to be resistant to sulfadoxine-pyrimethamine and several cases of delayed parasite clearance have been observed in patients with Plasmodium falciparum malaria treated with quinine. In this article we have introduced the concept of artemisinin- based combination therapy (ACT) and emphasize the use of empiric combination therapy for all patients with Plasmodium falciparum malaria to prevent development of drug resistance and to obtain additive and synergistic killing of parasite.
PDF(Pubmed)